8-K
filed February 7, 2025, 6:59 PM ET
ticker AEON
CIK 0001837607
regulatory
confidence high
sentiment negative
materiality 0.75
AEON Biopharma receives NYSE American delisting notice over stockholder deficit of $32.1M
AEON Biopharma, Inc.
- Received notice on Feb 3, 2025 for non-compliance with Section 1003(a)(i) requiring $2M+ stockholders' equity.
- Reported stockholders' deficit of $32.1M as of Sept 30, 2024 and losses in two of the three most recent fiscal years.
- Must submit a compliance plan by March 5, 2025; has until Aug 3, 2026 to regain compliance.
- If plan not accepted or fails, delisting proceedings will commence; shares will trade with ".BC" designation.
- No immediate impact on listing or business operations; company intends to submit a plan.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001837607-25-000010
- form_type
- 8-K
- ticker
- AEON
- cik
- 0001837607
- company_name
- AEON Biopharma, Inc.
- filed_at
- 2025-02-07T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:05.192665+00:00
- generated_at
- 2026-05-27T01:01:41.272466+00:00
- sec_items
- ["3.01", "9.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001837607-25-000010
- json_url
- https://secwatch.observer/filing/0001837607-25-000010.json
- markdown_url
- https://secwatch.observer/filing/0001837607-25-000010.md
- text_url
- https://secwatch.observer/filing/0001837607-25-000010.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1837607/000183760725000010/0001837607-25-000010-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1837607/000183760725000010/aeon-20250203x8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ILLR
Triller gets Nasdaq bid-price exception until June 30, 2026
Triller Group Inc.
June 2, 2026, 8:26 AM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w
Comparable filing
May 29, 2026, the Nasdaq Hearings Panel (the
“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant
Triller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,
2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following
a successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which
modified a previous December 26, 2025 decision by a Nasdaq Hearings Panel
Filing page
SEC filing
GENC
Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing
GENCOR INDUSTRIES INC
June 1, 2026, 4:09 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w
Comparable filing
May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY
Filing page
SEC filing
NUTR
NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026
NUSATRIP Inc
June 1, 2026, 7:10 AM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w
Comparable filing
May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”)
from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s
non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely
file its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended
March 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req
Filing page
SEC filing
ATNM
Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
Actinium Pharmaceuticals, Inc.
May 29, 2026, 5:10 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w
Comparable filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Filing page
SEC filing
CSAI
Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing
CLOUDASTRUCTURE, INC.
May 29, 2026, 5:09 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w
Comparable filing
May 26, 2026, Cloudastructure,
Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq
Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for
the period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which
requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional
time to review and confirm the accounting treatment for its outstand
Filing page
SEC filing
GURE
Gulf Resources receives Nasdaq delisting notice for late Q1 2026 10-Q filing
GULF RESOURCES, INC.
May 29, 2026, 4:45 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w
Comparable filing
May 26, 2026, Gulf Resources
(the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq
Stock Market LLC (“Nasdaq”), indicating that, as a result of not having timely filed its quarterly report on Form 10-Q for
the quarter ended March 31, 2026 (the “Form 10-Q”), and the Company remains delinquent in filing its annual report on Form
10-K for the year ended December 31, 2025 (the “Initial Delinquent Filing”), the Company is in non-compliance with Nasdaq
Listing Rule 5250(c)(1), which requires timely filing all required periodic financial reports wit
Filing page
SEC filing
ONFO
Onfolio receives Nasdaq delisting notice for insufficient equity ($1.22M vs $2.5M min)
Onfolio Holdings, Inc
May 29, 2026, 4:30 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w
Comparable filing
May 26, 2026, Onfolio Holdings Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Quarterly Report on Form 10-Q for the for the period ended March 31, 2026 reported stockholders’ equity of $1,216,603. As of the date of the Notice
Filing page
SEC filing
RR
Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing
RICHTECH ROBOTICS INC.
May 28, 2026, 4:49 PM ET
regulatory
Items 3.01, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 9.01
same event type: regulatory
similar materiality
This filing
February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w
Comparable filing
May 22, 2026, Richtech
Robotics Inc., a Nevada corporation (the “ Company ”) received a notice (the “ Notice ”) from the Listing
Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company is not in compliance
with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”), because it has not timely filed its Quarterly Report on Form 10-Q
for the period ended March 31, 2026 (the “ Form 10-Q ”) with the U.S. Securities and Exchange Commission (the “ SEC ”). The
Rule requires listed companies to timely file all required periodic financial reports with the SEC. The Com
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.